JS-014

N/A

Report date: 2022/08/31 10:13:03

Base Information

Drug NameJS-014
Drug Alias NameAWT-008JS-014Exenokine-21
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin 21 Receptor agonists
TargetsInterleukin 21 Receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, HepatocellularLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAnwita Biosciences Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAnwita Biosciences IncShanghai Junshi Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, HepatocellularLymphoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A